Ignite Creation Date:
2024-05-06 @ 3:32 PM
Last Modification Date:
2024-10-26 @ 1:51 PM
Study NCT ID:
NCT04666168
Status:
RECRUITING
Last Update Posted:
2020-12-14
First Post:
2020-11-11
Brief Title:
A Multicenter Clinical Study on the Safety and Efficacy of CAR-T in the Treatment of Relapsed Refractory Non Hodgkins Lymphoma
Sponsor:
Hebei Senlang Biotechnology Inc Ltd
Organization:
Hebei Senlang Biotechnology Inc Ltd
Study Overview
Official Title:
A Multicenter Clinical Study on the Safety and Efficacy of CAR-T in the Treatment of Relapsed Refractory Non Hodgkins Lymphoma
Status:
RECRUITING
Status Verified Date:
2020-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is a multicenter non randomized single arm open clinical trial The selected disease was relapsed refractory NHL and the disease was classified into highly aggressive lymphoma invasive lymphoma and inert lymphoma Highly invasive NHL included Burkitt lymphoma BL lymphoblastic lymphoma LBL high-grade B-cell lymphoma etc Invasive NHL includes diffuse large B-cell lymphoma mantle cell lymphoma and peripheral T-cell lymphoma Inert NHL contains follicular lymphoma small lymphocytic lymphoma and marginal zone lymphoma
Detailed Description:
A single car consists of scFv hinge region transmembrane region costimulatory domain and zeta subunit of CD3Prior to CAR-T cell infusion the patients will be subjected to preconditioning treatment After CAR-T cell infusion the patients will be evaluated for adverse reactions and efficacy
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None